Heath State Utility Values for Cost-Effectiveness Models

Research output: Contribution to journalEditorial

3 Citations (Scopus)

Abstract

Most contemporary clinical trials of new technologies collect health-related quality of life (HRQoL) data that can be used to generate utility values. Such data can be used to estimate differences in quality-adjusted life-year (QALY) gains in economic evaluations alongside clinical trials. However, such evaluations rarely represent all important differences in costs and outcomes, and cost-effectiveness models are commonly used to extrapolate beyond a trial’s time horizon to estimate longer-term costs and QALY gains [1].

HRQoL data collected in clinical trials are potentially important data sources to inform heath state utility values (HSUVs) that are key inputs to most cost-effectiveness models. In the ideal, the utility data collected in a clinical trial provide robust, sensitive preference-based estimates of all the HSUVs required to populate a cost-effectiveness model. Key issues that complicate the estimation of HSUVs using trial data include the sensitivity of selected preference-based measures (PBMs) to meaningful differences in HRQoL between health states, the small samples of utility data for some of the health states represented in cost-effectiveness models and the timing of the collection of utility data in clinical trials. As a result, separate utility studies may be required to more appropriately inform the HSUVs required to populate cost-effectiveness models.
Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalPharmacoeconomics
Volume35
Issue numberSuppl 1
DOIs
Publication statusPublished - 1 Dec 2017
Externally publishedYes

Keywords

  • QALY
  • quality of life
  • economic evaluation
  • Heath State Utility Values (HSUVs)

Fingerprint Dive into the research topics of 'Heath State Utility Values for Cost-Effectiveness Models'. Together they form a unique fingerprint.

  • Cite this